Mycobacterium Citations List: August 2022

Literature Citations

1. Total Synthesis of the Antimycobacterial Natural Product Chlorflavonin and Analogs via a Late-stage Ruthenium(II)-catalyzed ortho-C(sp(2))-H-hydroxylation. Berger, A., T. Knak, A.L. Kiffe-Delf, K. Mudrovcic, V. Singh, M. Njoroge, B.B. Burckhardt, M. Gopalswamy, B. Lungerich, L. Ackermann, H. Gohlke, K. Chibale, R. Kalscheuer, and T. Kurz. Pharmaceuticals, 2022. 15(8): 984. PMID[36015133]. PMCID[PMC9415896].
[PubMed]. TB_08_2022.

2. Indole-2-carboxamides as New Anti-mycobacterial Agents: Design, Synthesis, Biological Evaluation and Molecular Modeling against Mmpl3. Bhakhar, K.A., P.V. Vaghela, S.D. Varakala, S.J. Chudasma, N.D. Gajjar, P.R. Nagar, D. Sriram, and T.M. Dhameliya. ChemistrySelect, 2022. 7(26): e202201813. ISI[000824678600008].
[WOS]. TB_08_2022.

3. Antitubercular Activity of Novel 2-(Quinoline-4-yloxy)acetamides with Improved Drug-like Properties. Borsoi, A.F., L.M. Alice, N. Sperotto, A.S. Ramos, B.L. Abbadi, F.S. Macchi Hopf, A.D. Silva Dadda, R.S. Rambo, R.B. Madeira Silva, J.D. Paz, K. Pissinate, M.N. Muniz, C.E. Neves, L. Galina, L.C. González, M.A. Perelló, A. de Matos Czeczot, M. Leyser, S.D. de Oliveira, G. de Araújo Lock, B.V. de Araújo, T.D. Costa, C.V. Bizarro, L.A. Basso, and P. Machado. ACS Medicinal Chemistry Letters, 2022. 13(8): p. 1337-1344. PMID[35978694]. PMCID[PMC9376999].
[PubMed]. TB_08_2022.

4. Design, Synthesis and Biological Evaluation of Novel Spiro-chroman-2,4 '-piperidin-4-one Analogs as Anti-tubercular Agents. Chitti, S., A. Nandikolla, Y.M. Khetmalis, K. Van Calster, B.V.S. Kumar, B.K. Kumar, S. Murugesan, D. Cappoen, and K. Sekhar. Chemistry & Biodiversity, 2022. 19(8): e202200304. PMID[35821618].
[PubMed]. TB_08_2022.

5. Synthesis, Molecular Docking, and Biological Evaluation of Novel 1,2,4-Triazole-isatin Derivatives as Potential Mycobacterium tuberculosis Shikimate Kinase Inhibitors. Dadlani, V.G., H. Chhabhaiya, R.R. Somani, and P.K. Tripathi. Chemical Biology & Drug Design, 2022. 100(2): p. 230-244. PMID[35434882].
[PubMed]. TB_08_2022.

6. N'-Substituted 4-Phenylpicolinohydrazonamides with Thiosemicarbazone Moiety as New Potential Antitubercular Agents: Synthesis, Structure and Evaluation of Antimicrobial Activity. Gobis, K., M. Szczesio, A. Olczak, I. Mazerant-Politowicz, D. Ziembicka, B. Pacholczyk-Sienicka, E. Augustynowicz-Kopeć, A. Głogowska, I. Korona-Głowniak, and A. Fruziński. Materials, 2022. 15(16): 5513. PMID[36013649]. PMCID[PMC9414056].
[PubMed]. TB_08_2022.

7. Synthesis and Assessment of the in Vitro and ex Vivo Activity of Salicylate synthase (Mbti) Inhibitors as New Candidates for the Treatment of Mycobacterial Infections. Mori, M., G. Stelitano, A. Griego, L.R. Chiarelli, G. Cazzaniga, A. Gelain, E. Pini, M. Camera, P. Canzano, A. Fumagalli, E. Scarpa, C. Cordiglieri, L. Rizzello, S. Villa, and F. Meneghetti. Pharmaceuticals, 2022. 15(8): 992. PMID[36015139]. PMCID[PMC9413995].
[PubMed]. TB_08_2022.

8. Discovery of Potent Antitubercular Agents: Design, Synthesis and Biological Evaluation of 4-(3-(4-Substitutedpiperazin-1-yl)-quinoxalin-2-yl)-naphthalen-1-ol Analogues. Nandikolla, A., Y. Mahadu Khetmalis, K. Mahalakshmi Naidu, B. Karan Kumar, S. Murugesan, and K.V.G. Chandra Sekhar. Toxicology In Vitro, 2022. 82: 105370. PMID[35489549].
[PubMed]. TB_08_2022.

9. The First Synthesis of Podocarflavone A and Its Analogs and Evaluation of Their Antimycobacterial Potential against Mycobacterium tuberculosis with the Support of Virtual Screening. Puranik, N.V., S. Swami, A.V. Misar, R. Mamgain, S.S. Gulawani, Dhiman, Sarkar, and P. Srivastava. Natural Product Research, 2022. 36(15): p. 3879-3886. PMID[33663286].
[PubMed]. TB_08_2022.

10. Novel Organic Salts Based on Mefloquine: Synthesis, Solubility, Permeability, and in Vitro Activity against Mycobacterium tuberculosis. Silva, D., M.V.C. Lopes, Ž. Petrovski, M.M. Santos, J.P. Santos, S.F. Yamada-Ogatta, M.L.F. Bispo, M.V.N. de Souza, A.R.C. Duarte, M.C.S. Lourenço, R.S.B. Gonçalves, and L.C. Branco. Molecules, 2022. 27(16). PMID[36014405]. PMCID[PMC9412322].
[PubMed]. TB_08_2022.

11. Minimum Inhibitory Concentration of Cycloserine against Mycobacterium tuberculosis Using the MGIT 960 System and a Proposed Critical Concentration. Wu, X., Y. Shang, W. Ren, W. Wang, Y. Wang, Z. Xue, S. Li, and Y. Pang. International Journal of Infectious Diseases, 2022. 121: p. 148-151. PMID[35577251].
[PubMed]. TB_08_2022.

12. In Vitro Susceptibility of Nontuberculous Mycobacteria to Tedizolid. Zhang, H., W. Hua, S. Lin, Y. Zhang, X. Chen, S. Wang, J. Chen, and W. Zhang. Infection and Drug Resistance, 2022. 15: p. 4845-4852. PMID[36045871]. PMCID[PMC9422992].
[PubMed]. TB_08_2022.

13. Design, Synthesis, and Biological Evaluation of Pyrrole-2-carboxamide Derivatives as Mycobacterial Membrane Protein Large 3 Inhibitors for Treating Drug-resistant Tuberculosis. Zhao, H., Y. Gao, W. Li, L. Sheng, K. Cui, B. Wang, L. Fu, M. Gao, Z. Lin, X. Zou, M. Jackson, H. Huang, Y. Lu, and D. Zhang. Journal of Medicinal Chemistry, 2022. 65(15): p. 10534-10553. PMID[35915958]. PMCID[PMC9379527].
[PubMed]. TB_08_2022.

Patent Citations

This month, no relevant Mycobacterium patents were identified.